52X Stock Overview
Operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Magle Chemoswed Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.94 |
| 52 Week High | SEK 4.06 |
| 52 Week Low | SEK 1.88 |
| Beta | 0.54 |
| 11 Month Change | -12.50% |
| 3 Month Change | -12.50% |
| 1 Year Change | 40.00% |
| 33 Year Change | -1.34% |
| 5 Year Change | n/a |
| Change since IPO | 34.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 52X | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -3.9% | -0.6% | -1.8% |
| 1Y | 40.0% | 15.3% | 13.2% |
Return vs Industry: 52X exceeded the German Life Sciences industry which returned 18.6% over the past year.
Return vs Market: 52X exceeded the German Market which returned 16.1% over the past year.
Price Volatility
| 52X volatility | |
|---|---|
| 52X Average Weekly Movement | 6.2% |
| Life Sciences Industry Average Movement | 6.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 52X has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 52X's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 147 | Justin Pierce | www.maglechemoswed.com |
Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company’s microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures.
Magle Chemoswed Holding AB (publ) Fundamentals Summary
| 52X fundamental statistics | |
|---|---|
| Market cap | €58.45m |
| Earnings (TTM) | €1.44m |
| Revenue (TTM) | €17.96m |
40.7x
P/E Ratio3.3x
P/S RatioIs 52X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 52X income statement (TTM) | |
|---|---|
| Revenue | SEK 209.21m |
| Cost of Revenue | SEK 25.74m |
| Gross Profit | SEK 183.48m |
| Other Expenses | SEK 166.73m |
| Earnings | SEK 16.75m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | 0.91 |
| Gross Margin | 87.70% |
| Net Profit Margin | 8.00% |
| Debt/Equity Ratio | 25.4% |
How did 52X perform over the long term?
See historical performance and comparison